Gilead makes Truvada, the only FDA-approved drug to prevent the transmission of HIV.
The agreement struck between Gilead and HHS will last until Dec. 31, 2025.
Truvada sells for about $1,600 to $2,000 a month in the U.S.
Gilead has faced criticism from AIDS activists who have pressured Gilead to make Truvada more widely available by breaking its patent or lowering its cost.
“Securing this commitment is a major step in the Trump administration’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030,” Mr. Azar said.
More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal
